Chelsea Griffiths
Newcastle University
6 Papers
Chelsea Griffiths is an academic researcher from Newcastle University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 4 publications. Previous affiliations of Chelsea Griffiths include Freeman Hospital.
Chat about Author
Papers
FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2
Teresa Brevini,Mailis Maes,Gwilym J. Webb,Binu John,Claudia D. Fuchs,Gustav Buescher,Lu Wang,Chelsea Griffiths,Marnie Brown,William E. Scott,P. Pereyra-Gerber,William Gelson,Stephanie Brown,Scott Dillon,Daniele Muraro,Joanne Sharp,Megan Neary,Helen Box,Lee Tatham,James P. Stewart,Paul Curley,Henry Pertinez,Sally Forrest,Petra Mlcochova,Sagar S. Varankar,Mahnaz Darvish-Damavandi,Victoria Mulcahy,Rhoda E. Kuc,Thomas L Williams,James A. Heslop,Davide Rossetti,Olivia C. Tysoe,Vasileios Galanakis,Marta Vila-Gonzalez,Thomas W. M. Crozier,Johannes Bargehr,Sanjay Sinha,Sara Upponi,Corrina Fear,Lisa Swift,Kourosh Saeb-Parsy,Susan E. Davies,Axel Wester,Hannes Hagström,Espen Melum,D. K. Clements,Peter Humphreys,Joanne Herriott,Edyta Kijak,Helen Cox,Chloe Bramwell,Anthony J. Valentijn,Christopher J. R. Illingworth,Bassam Dahman,Dustin R Bastaich,Raphaella D. Ferreira,Thomas Marjot,Eleanor Barnes,Andrew M. Moon,A. Sidney Barritt,Ravindra K. Gupta,Stephen Baker,Anthony P. Davenport,G. Corbett,Vassilis G. Gorgoulis,Simon J.A. Buczacki,Joo-Hyeon Lee,Nicholas J Matheson,Michael Trauner,Andrew J. Fisher,Paul Gibbs,Andrew J. Butler,Christopher A. Watson,George F. Mells,Gordon Dougan,Andrew Owen,Ansgar W. Lohse,Ludovic Vallier,Fotios Sampaziotis +78 more
TL;DR: In this article , the authors show that the farnesoid X receptor (FXR) is a direct regulator of ACE2 transcription in several tissues affected by COVID-19, including the gastrointestinal and respiratory systems.
Maximising organs for donation: the potential for ex-situ normothermic machine perfusion.
Chelsea Griffiths,Chelsea Griffiths,William E. Scott,William E. Scott,Simi Ali,Simi Ali,Andrew J. Fisher,Andrew J. Fisher +7 more
TL;DR: This review will explore some of the novel therapeutics currently being added to perfusion platforms during NMP experimentally in an attempt to improve organ function and post-transplant outcomes.
5
Evaluating the immunomodulatory potential of human amniotic epithelial cells as a therapeutic in ex vivo donor lung reconditioning
TL;DR: The potential for hAECs to reduce the production of key inflammatory cytokines (IL-8 and TNFα) from pro-inflammatory macrophages and activated pulmonary endothelium, alongside lowering expression of key endothelia activation markers is demonstrated.
2
Modeling the Effects of IL-1β-mediated Inflammation During Ex Vivo Lung Perfusion Using a Split Human Donor Model.
Thomas L. Pither,Lu Wang,Lucy Bates,Morvern Isabel Morrison,Catriona Charlton,Chelsea Griffiths,Jamie Liam Macdonald,Venetia Bigley,Maria Mavridou,Joseph Barsby,L J Borthwick,John H. Dark,William E. Scott,Simi Ali,Andrew J. Fisher +14 more
TL;DR: In this article , the authors investigated the mechanism underlying IL-1β-mediated donor lung injury using a paired single-lung EVLP model and found that neutrophil numbers were significantly lower in perfusate samples collected from the IL- 1β-stimulated lungs consistent with increased neutrophIL adhesion.
1
Ex Vivo Lung Perfusion: A Platform for Donor Lung Assessment, Treatment and Recovery
Luke Milross,Chelsea Griffiths,Andrew J. Fisher +2 more
- 27 Sep 2021
TL;DR: Compared to static cold storage (SCS), ex vivo lung perfusion (EVLP) offers clinicians unrivalled opportunity for rigorous objective assessment of donor lungs in conditions replicating normal physiology, thus allowing for better informed decision-making in suitability assessments.